Clinical and neurohumoral differences between spirapril and captopril in mild to moderate chronic congestive heart failure

Autor: Stan A.J. van den Broek, Pieter A. de Graeff, Hans L. Hillege, Wiek H. van Gilst, Harry Wesseling, Kong I. Lie, Dirk J. van Veldhuisen

Publikováno v: Journal of Cardiac Failure. 3:165-171

This study was done to determine whether the difference in duration of action of the long-acting angiotensin-converting enzyme (ACE) inhibitor spirapril compared with the short-acting ACE inhibitor captopril affects clinical efficacy in patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::babc2c2ebd4beb0ad6c033068546a6ad
https://doi.org/10.1016/s1071-9164(97)90012-9

Effects of spirapril and captopril on regional blood flow in chronic congestive heart failure

Autor: Kong I. Lie, Louis Journée, Dirk J. van Veldhuisen, Armand R. J. Girbes, Harry Wesseling, Pieter A. de Graeff, Andries J. Smit, Hans L. Hillege, Wiek H. van Gilst, Stan A.J. van den Broek

Publikováno v: van den Broek, S A J, de Graeff, P A, Smit, A J, Girbes, A R J, Journée, L, van Gilst, W H, Hillege, H, van Veldhuisen, D J, Wesseling, H & Lie, K I 1995, ' Effects of spirapril and captopril on regional blood flow in chronic congestive heart failure : A comparison between a short-and a long-acting angiotensin-converting enzyme inhibitor ', Journal of Cardiovascular Pharmacology, vol. 25, no. 1, pp. 105-112 . https://doi.org/10.1097/00005344-199501000-00017
Journal of Cardiovascular Pharmacology, 25(1), 105-112
Journal of Cardiovascular Pharmacology, 25(1), 105-112. Lippincott Williams and Wilkins Ltd.

Spirapril is a new angiotensin-converting enzyme (ACE) inhibitor with a long duration of action. To determine whether duration of inhibition of serum ACE activity may affect regional blood flow (RBF), we compared spirapril with captopril, an ACE inhi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4767abc00f48aa117acf6e97d38b7f83
http://www.scopus.com/inward/record.url?scp=0028795191&partnerID=8YFLogxK

Comparison between New York Heart Association Classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy

Autor: Martin L.J. Landsman, Dirk J. van Veldhuisen, Stan A.J. van den Broek, Pieter A. de Graeff, Kong I. Lie, Hans L. Hillege

Publikováno v: The American Journal of Cardiology. 70:359-363

To compare the value of the New York Heart Association (NYHA) classification and measurement of peak oxygen consumption (VO2) in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure (CHF

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1358709c110f56c82a6c39a55d708a2c
https://doi.org/10.1016/0002-9149(92)90619-a

Glucose-insulin-potassium infusion in patients with acute myocardial infarction without signs of heart failure: the Glucose-Insulin-Potassium Study (GIPS)-II

Autor: Tone Svilaas, Jorik R. Timmer, Iwan C. C. van der Horst, José P.S. Henriques, Felix Zijlstra, Jan-Henk E. Dambrink, Jan Paul Ottervanger, Stan A.J. van den Broek

Publikováno v: Journal of the American College of Cardiology, 47(8), 1730-1731. ELSEVIER SCIENCE INC
Journal of the American College of Cardiology, 47(8), 1730-1731. Elsevier USA

To the Editor: Metabolic support through glucose-insulin-potassium (GIK), in adjunct to reperfusion therapy, might improve outcome in patients with ST-segment elevation myocardial infarction (STEMI) ([1][1]). The Glucose-Insulin-Potassium Study (GIPS

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee96ab498e7a8b12f5490b23f3fd5384
https://pubmed.ncbi.nlm.nih.gov/16631017

Decompensation of chronic heart failure associated with pregabalin in a 73-year-old patient with postherpetic neuralgia: a case report

Autor: Ruth H. E. De Smedt, Flora M. Haaijer-Ruskamp, Trijntje Jaarsma, Stan A.J. van den Broek

Publikováno v: British Journal of Clinical Pharmacology, 66(2), 327-328. Wiley

Pregabalin is a relatively new drug in the treatment of peripheral neuropathic pain in adults. The most common associated adverse drug events (ADEs) are dizziness and somnolence, followed by peripheral oedema and weight gain [1–4]. There has been o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e152ab08d3c050d1529cc1c8561ce428
https://doi.org/10.1111/j.1365-2125.2008.03196.x